Specifically, hypermethylation of BCL2L13 promoter in ccRCC is independent of patients’ age, gender, race, clinical stages, lymph node metastasis status and tumor grade (Additional file 3). This evidence concerns the gene BCL2L13 and nonpapillary renal cell carcinoma.